Literature DB >> 10718487

Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro.

M D Walsh1, S M Luckie, M C Cummings, T M Antalis, M A McGuckin.   

Abstract

Increased expression of the epithelial mucin MUC1 has been linked to tumor aggressiveness in human breast carcinoma. Recent studies have demonstrated that overexpression of MUC1 interferes with cell-substrate and cell-cell adhesion by masking cell surface integrins and E-cadherin. Additionally, the cytoplasmic tail of MUC1 is involved in signal transduction and interactions with catenins. In the present study, we have examined the in vitro expression of MUC1 mRNA and protein in a panel of 14 human breast cancer cell lines using northern blotting, western blotting, immunocytochemistry, and flow cytometry. Considerable variability of expression was noted not only between cell lines but also within several individual lines. Many cell lines such as BT 20, KPL-1, and T47D expressed abundant MUC1 whilst others such as MDA-MB-231 and MCF-7 showed intermediate expression, and MDA-MB-435 and MDA-MB-453 expressed very low levels. Low levels of MUC1 expression were associated with decreased expression of cytokeratin and increased expression of vimentin. Additionally, 12 of the cell lines were established as xenografts in immunocompromised (SCID) mice, and MUC1 expression in both the primary tumors as well as metastases was assessed immunohistochemically. In general, in vivo expression mirrored in vitro expression, although there was reduced in vivo expression in T47D and ZR-75-1 xenografts. Although we showed no correlation between tumorigenicity or metastasis and MUC1 expression, this study will assist development of experimental models to assess the influence of MUC1 of on breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10718487     DOI: 10.1023/a:1006345301364

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  20 in total

1.  Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.

Authors:  Deepak Raina; Rehan Ahmad; Maya Datt Joshi; Li Yin; Zekui Wu; Takeshi Kawano; Baldev Vasir; David Avigan; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

2.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

3.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

4.  Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.

Authors:  Liqun Yu; Lawrence Wang; Chengjian Mao; Darjan Duraki; Ji Eun Kim; Rui Huang; William G Helferich; Erik R Nelson; Ben Ho Park; David J Shapiro
Journal:  Cancer Lett       Date:  2018-11-09       Impact factor: 8.679

5.  Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.

Authors:  Carolyn M Klinge; Brandie N Radde; Yoannis Imbert-Fernandez; Yun Teng; Margarita M Ivanova; Sabra M Abner; Alexandra L Martin
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.261

Review 6.  Adenoviral vectors for prodrug activation-based gene therapy for cancer.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

7.  Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.

Authors:  Pawel Ciborowski; Olivera J Finn
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

8.  A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis.

Authors:  Steven T Huyn; Jeremy B Burton; Makoto Sato; Michael Carey; Sanjiv S Gambhir; Lily Wu
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

9.  Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.

Authors:  J C Doloff; Y Jounaidi; D J Waxman
Journal:  Cancer Gene Ther       Date:  2010-09-24       Impact factor: 5.987

10.  Using a cell line breast cancer progression system to identify biomarker candidates.

Authors:  Ten-Yang Yen; Nicole Haste; Leslie C Timpe; Christina Litsakos-Cheung; Roger Yen; Bruce A Macher
Journal:  J Proteomics       Date:  2013-11-18       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.